The 19th Frost & Sullivan Global Growth, Innovation and Leadership Summit & 4th New Investment Conference - Life Sciences New Investment Summit Forum, hosted by Frost & Sullivan (Frost & Sullivan, abbreviated as F&S), a globally leading growth consulting firm, was successfully held in Shanghai on August 28, 2025. The forum brought together more than 50 industry leaders, biopharmaceutical companies, medical device enterprises, investment institutions and professional service providers. With the theme of "Strengthening Foundations Internally and Steadily Riding the Waves," it focused on cutting-edge trends, innovative technologies and globalization development strategies in the field of life sciences, aiming to promote industrial development and global cooperation.
At this forum, Lin Zirong, Executive Director of Canova Biopharmaceutical Co., Ltd., shared a keynote speech titled 'Exploration and Practice of Mitochondrial Medicine in Longevity Medicine'.
Lin Zirong, Executive Director of Canuo Biopharmaceutical Co., Ltd.
The following are the key points of Lin Zirong's speech:
I. Development Background and Current Situation of Longevity Medicine
Lin Zirong pointed out that the current global population aging problem is becoming increasingly severe, especially in China. By 2024, the population aged 65 and above in China will reach 220 million, accounting for 15.8% of the total population. The compound annual growth rate from 2019 to 2024 was 4.8%, and it is expected that by 2030 it will increase to 270 million, accounting for more than 19%. Aging is accompanied by a high incidence of aging-related diseases such as cardiovascular diseases and neurodegenerative diseases, which has become a major social challenge. In 2018, 'aging' was included in the International Classification of Diseases by the World Health Organization. In 2019, 36 institutions including Harvard Medical School jointly declared in 'Science' that aging is an intervenable disease process, promoting the medical concept from 'disease treatment' to 'healthy aging'.
At the policy level, 'actively addressing population aging' has been elevated to a national strategy of China. In 2024, the State Council's 'Opinions on Developing the Silver Economy to Enhance the Well-being of the Elderly' named policy documents after 'silver economy' for the first time, clearly defining the development of anti-aging industries; the '14th Five-Year Plan' lists life health as a major frontier field for scientific and technological projects, improving the rapid review mechanism for innovative medicines; in 2025, twelve departments including the Ministry of Commerce issued the 'Special Action Plan to Promote Healthy Consumption', providing support for the development of longevity medicine from top-level design. It is estimated that the economic benefits generated by life extension interventions each year can reach 38 trillion US dollars, and healthy aging has become key to alleviating the medical burden and unlocking longevity dividends.
Longevity medicine, as an emerging interdisciplinary field, is based on molecular biology, clinical medicine, and data science. It integrates technologies such as regenerative medicine, genomics, and AI. Its core is to quantify aging indicators (such as epigenetic clocks, telomere length, mitochondrial disorders), develop intervention technologies (such as Senolytics drugs, NAD+Supplements) to achieve the goal of 'delaying the aging process and extending healthy lifespan'. Its system consists of four pillars: a multi-level aging assessment system (biomarker testing + functional status monitoring), a precise intervention technology matrix (lifestyle intervention + biotechnology intervention + cutting-edge regeneration technology), an integrated health management pathway (three-level service at longevity clinics), and an industry-university-research collaborative ecosystem (medical services + industrial integration + capital empowerment), marking a transformation of the medical paradigm from passive treatment to active intervention.
II. The Core Value of Mitochondrial Medicine in Longevity Medicine
Lin Zirong emphasized that mitochondria, as the cell's energy factory and signaling hub, play a central role in energy (ATP) supply and signal regulation. They are the key foundation for maintaining cellular function and homeostasis, and their dysfunction is a key cause of aging and related diseases. It can trigger a chain reaction including insufficient energy, increased ROS, chronic inflammation, etc., which can lead to cardiovascular diseases, neurodegenerative diseases, and more. Mitochondrial medicine covers the entire scenario of 'detection-intervention' and is an important branch of longevity medicine. Its core goal is to delay the aging process by maintaining mitochondrial homeostasis.
Among the current mainstream anti-aging technologies, targeted mitochondrial interventions hold an important position. NAD+Nicotinamide adenine dinucleotide (NAD) serves as a key molecule for mitochondrial function. It is not only a core cofactor in the tricarboxylic acid cycle and electron transport chain but also an NAD+The sole substrate of digestive enzymes, which significantly declines with age and the onset of diseases, is a 'metabolic hub' connecting aging with various diseases. Antioxidant drugs are classified into two categories at home and abroad: one category consists of 'well-evidenced, clearly understood mechanisms, and safe drugs'; the other category includes 'promising but lacking evidence or controversial drugs'. NAD+It is recognized as a 'class of anti-aging drugs' and is recommended by consensus guidelines such as 'Chinese Expert Consensus on the Interventional Study of Anti-Aging Drugs (2024)', 'Chinese Expert Consensus on the Clinical Assessment and Intervention of Vascular Aging (2024 Edition)', and 'Guidelines for Chronic Disease Management of Geriatric Cognitive Dysfunction'. It complements NAD.+Can improve the occurrence or progression of aging-related diseases such as vascular aging and cognitive impairment. NAD+Due to its clear mechanism and high security, it has become one of the most mature directions for clinical translation. Relevant studies have confirmed that it can enhance the energy supply to myocardial and brain cells, improve ovarian aging and chronic fatigue syndrome, among other issues, providing a quantifiable and verifiable intervention pathway for longevity medicine.
III. Practice of Canuo Biotechnology and Future Prospects of the Industry
Lin Zirong introduced that Canuo Biotech takes mitochondrial medicine as the core and constructs a closed-loop business model of 'testing - intervention - retesting', achieving visual and quantifiable anti-aging results. In terms of testing, Canuo Biotech relies on its independently developed NAD+The AI intelligent detection platform for inspection technology can accurately evaluate NAD.+Metabolic level provides a basis for assessing the degree of aging. In terms of intervention, Cano Biotech holds the only globally approved NAD+Medicine - Enalapril®Targeted regulation of NAD+Metabolic anti-aging related disease innovative drug pipelines and a series of mitochondrial nutrients provide alternative solutions for mitochondrial dysfunction in different populations. After intervention, the metabolic response curve after NAD+ intervention is analyzed through the cloud AI platform, automatically adjusting dosages and formulations to achieve a closed-loop management of 'data-feedback-optimization'. ConnaBio is accelerating the universalization of personalized anti-aging and related disease solutions through AI, and will become a benchmark enterprise in the global mitochondrial medicine field.
Looking ahead, Lin Zirong believes that longevity medicine will shift from 'extending lifespan' to 'improving quality of life.' The core is to popularize personalized anti-aging plans through multi-omics and AI technology, compressing the survival period with chronic diseases and achieving 'senior years without illness.' Kangnuo Biotech will continue to focus on research on mitochondrial dysfunction, promote the standardization of detection technology, the precision of intervention plans, and the clinical transformation of regeneration technology. It is committed to becoming a global leader in mitochondrial medicine and health product providers, offering the 'Chinese solution' to the global aging challenge.
